To examine updated trends in breast cancer incidence among Asian American, Native Hawaiian, and Pacific Islander women from 2000 to 2022.
Approach:
Data Source: Utilized data from the NCI SEER Program covering female invasive breast cancer cases diagnosed from January 1, 2000, through December 31, 2022.
Population Coverage: Data included 21 registries across 14 states, representing 66.4% of the Asian American, Native Hawaiian, and Pacific Islander population.
Ethnic Disaggregation: Analyzed trends for 7 Asian American and 2 Native Hawaiian and Pacific Islander groups, as well as comparisons with other racial and ethnic groups.
Key Findings:
Asian American, Native Hawaiian, and Pacific Islander women had the steepest rise in breast cancer rates at 3.3% per year from 2017 to 2021.
Breast cancer incidence varied across different Asian American, Native Hawaiian, and Pacific Islander ethnic groups.
Estrogen receptor-positive breast cancer rates increased significantly among Asian American women, while estrogen receptor-negative rates remained stable or decreased.
The fastest increase in triple-negative breast cancer incidence was observed in females aged 65 years or older at 5.5% from 2016 to 2019.
Incidence rates for women under 50 years increased by 4.0% annually from 2016 to 2019.
Interpretation:
The study highlights concerning trends in breast cancer incidence among Asian American, Native Hawaiian, and Pacific Islander women, particularly among younger cohorts and specific ethnic groups.
Limitations:
National breast cancer incidence trends for disaggregated ethnic groups had not been reported since 2014 due to lack of annual population estimates.
The study is based on deidentified data, which limits the ability to assess individual-level factors.
Conclusion:
The findings indicate a need for further research into the underlying drivers of increasing breast cancer rates in these populations.
by Scarlett Lin Gomez, Meg McKinley, Mikayla Chan, Katherine Lin, Mandi Yu, Steve Scoppa, Todd Gibson, Kohei Miyagi, Brenda Y. Hernandez, Anne-Michelle Noone, Allison Kurian, Iona Cheng, Salma Shariff-Marco
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Saci-IO HR+ trial, which were presented at the 2026 ESMO Breast Cancer Congress.